Steven Pieper - 22 Nov 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Financial Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
22 Nov 2024
Net transactions value
+$30,199
Form type
4
Filing time
26 Nov 2024, 17:00:27 UTC
Previous filing
31 Jan 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Options Exercise $30,199 +19,483 +1.4% $1.55 1,441,820 22 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -16,843 -100% $0.000000 0 22 Nov 2024 Common Stock 16,843 $1.55 Direct F1
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -2,640 -100% $0.000000 0 22 Nov 2024 Common Stock 2,640 $1.55 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on February 2018, 2019, 2021, and 2021.
F2 The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on June 2018, 2019, 2021, and 2021.

Remarks:

Chief Financial Officer